{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:58:11Z","timestamp":1791903491104,"version":"4.3.4"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T00:00:00Z","timestamp":1623715200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Signalling"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.cellsig.2021.110038","type":"journal-article","created":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T02:53:40Z","timestamp":1620701620000},"page":"110038","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["AKR1C3 decreased CML sensitivity to Imatinib in bone marrow microenvironment via dysregulation of miR-379-5p"],"prefix":"10.1016","volume":"84","author":[{"given":"Di","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanwan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaizhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinglong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cellsig.2021.110038_bb0005","doi-asserted-by":"crossref","first-page":"939","DOI":"10.3389\/fonc.2019.00939","article-title":"BCR-ABL independent mechanisms of resistance in chronic myeloid leukemia","volume":"9","author":"Loscocco","year":"2019","journal-title":"J. Front Oncol."},{"issue":"10","key":"10.1016\/j.cellsig.2021.110038_bb0010","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1248\/bpb.b20-00325","article-title":"Emodin inhibits resistance to Imatinib by downregulation of Bcr-Abl and STAT5 and allosteric inhibition in chronic myeloid leukemia cells.[J]","volume":"43","author":"Wang","year":"2020","journal-title":"Biol. Pharm. Bull."},{"issue":"1","key":"10.1016\/j.cellsig.2021.110038_bb0015","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1038\/s41598-019-38672-x","article-title":"Novel mutations in the kinase domain of BCR-ABL gene causing imatinib resistance in chronic myeloid leukemia patients","volume":"9","author":"Chandrasekhar","year":"2019","journal-title":"[J] Sci Rep"},{"issue":"20","key":"10.1016\/j.cellsig.2021.110038_bb0020","doi-asserted-by":"crossref","first-page":"11305","DOI":"10.1021\/acs.jmedchem.9b02138","article-title":"Overview of AKR1C3: Inhibitor Achievements and Disease Insights","volume":"63","author":"Liu","year":"2020","journal-title":"[J] J Med Chem"},{"issue":"18","key":"10.1016\/j.cellsig.2021.110038_bb0025","doi-asserted-by":"crossref","first-page":"10396","DOI":"10.1021\/acs.jmedchem.0c00939","article-title":"Development of novel AKR1C3 inhibitors as new potential treatment for castration-resistant prostate cancer","volume":"63","author":"Endo","year":"2020","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.cellsig.2021.110038_bb0030","article-title":"Dual inhibitory action of a Novel AKR1C3 inhibitor on both full-length AR and the variant AR-V7 in enzalutamide resistant metastatic castration resistant prostate cancer","volume":"12","author":"Kafka","year":"2020","journal-title":"[J] Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.cellsig.2021.110038_bb0035","article-title":"AKR1C3 Is associated with better survival of patients with endometrial carcinomas","volume":"9","author":"Hojnik","year":"2020","journal-title":"[J] J Clin Med"},{"issue":"20","key":"10.1016\/j.cellsig.2021.110038_bb0040","doi-asserted-by":"crossref","first-page":"12032","DOI":"10.1111\/jcmm.15831","article-title":"The AKR1C3\/AR-V7 complex maintains CRPC tumour growth by repressing B4GALT1 expression.[J]","volume":"24","author":"Wang","year":"2020","journal-title":"J. Cell. Mol. Med."},{"issue":"7","key":"10.1016\/j.cellsig.2021.110038_bb0045","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1080\/10428194.2020.1728746","article-title":"An AKR1C3-specific prodrug with potent anti-tumor activities against T-ALL.[J]","volume":"61","author":"Wang","year":"2020","journal-title":"Leuk. Lymphoma"},{"issue":"3","key":"10.1016\/j.cellsig.2021.110038_bb0050","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.bbrc.2019.06.119","article-title":"Aryl hydrocarbon receptor counteracts pharmacological efficacy of doxorubicin via enhanced AKR1C3 expression in triple negative breast cancer cells","volume":"516","author":"Yamashita","year":"2019","journal-title":"[J] Biochem Biophys Res Commun"},{"issue":"9","key":"10.1016\/j.cellsig.2021.110038_bb0055","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1007\/s00204-018-2258-0","article-title":"Aldo-keto reductase 1C3 (AKR1C3): a missing piece of the puzzle in the dinaciclib interaction profile.[J]","volume":"92","author":"Novotna","year":"2018","journal-title":"Arch. Toxicol."},{"issue":"22","key":"10.1016\/j.cellsig.2021.110038_bb0060","doi-asserted-by":"crossref","first-page":"5934","DOI":"10.1016\/j.bmc.2018.10.044","article-title":"Screening, synthesis, crystal structure, and molecular basis of 6-amino-4-phenyl-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitriles as novel AKR1C3 inhibitors","volume":"26","author":"Zheng","year":"2018","journal-title":"[J] Bioorg Med Chem"},{"key":"10.1016\/j.cellsig.2021.110038_bb0065","doi-asserted-by":"crossref","first-page":"108638","DOI":"10.1016\/j.steroids.2020.108638","article-title":"Type 5 17-hydroxysteroid dehydrogenase\/prostaglandin F synthase (AKR1C3) inhibition and potential anti-proliferative activity of cholest-4-ene-3,6-dione in MCF-7 breast cancer cells.[J]","volume":"159","author":"Sali","year":"2020","journal-title":"Steroids"},{"issue":"1","key":"10.1016\/j.cellsig.2021.110038_bb0070","article-title":"Small molecule GL-V9 protects against colitis-associated colorectal cancer by limiting NLRP3 inflammasome through autophagy","volume":"7","author":"Zhao","year":"2017","journal-title":"[J] Oncoimmunology"},{"issue":"W1","key":"10.1016\/j.cellsig.2021.110038_bb0075","doi-asserted-by":"crossref","first-page":"W98","DOI":"10.1093\/nar\/gkx247","article-title":"GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses.[J]","volume":"45","author":"Tang","year":"2017","journal-title":"Nucleic Acids Res."},{"issue":"3","key":"10.1016\/j.cellsig.2021.110038_bb0080","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/mc.22540","article-title":"Oroxylin a reverses the drug resistance of chronic myelogenous leukemia cells to imatinib through CXCL12\/CXCR7 axis in bone marrow microenvironment.[J]","volume":"56","author":"Li","year":"2017","journal-title":"Mol. Carcinog."},{"issue":"7","key":"10.1016\/j.cellsig.2021.110038_bb0085","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.1021\/acs.jmedchem.9b00090","article-title":"Potent and Highly Selective Aldo-Keto Reductase 1C3 (AKR1C3) Inhibitors Act as Chemotherapeutic Potentiators in Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia","volume":"62","author":"Verma","year":"2019","journal-title":"[J] J Med Chem"},{"issue":"10","key":"10.1016\/j.cellsig.2021.110038_bb0090","first-page":"472","article-title":"AKR1C3, a crucial androgenic enzyme in prostate cancer, promotes epithelial-mesenchymal transition and metastasis through activating ERK signaling","volume":"36","author":"Wang","year":"2018","journal-title":"[J] Urol Oncol"},{"issue":"3","key":"10.1016\/j.cellsig.2021.110038_bb0095","first-page":"4138","article-title":"Diagnostic and prognostic values of AKR1C3 and AKR1D1 in hepatocellular carcinoma","volume":"13","author":"Zhu","year":"2021","journal-title":"[J] Aging (Albany NY)"},{"issue":"1\u20132","key":"10.1016\/j.cellsig.2021.110038_bb0100","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jsbmb.2011.12.012","article-title":"Overexpression of aldo-keto reductase 1C3 (AKR1C3) in LNCaP cells diverts androgen metabolism towards testosterone resulting in resistance to the 5alpha-reductase inhibitor finasteride.[J]","volume":"130","author":"Byrns","year":"2012","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"3","key":"10.1016\/j.cellsig.2021.110038_bb0105","first-page":"124","article-title":"Prostate cancer: Breaking AKR1C3-mediated enzalutamide resistance by inhibiting androgen synthesis","volume":"12","author":"Thoma","year":"2015","journal-title":"[J] Nat Rev Urol"},{"issue":"11","key":"10.1016\/j.cellsig.2021.110038_bb0110","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.7150\/ijms.9239","article-title":"AKR1C3 overexpression mediates methotrexate resistance in choriocarcinoma cells","volume":"11","author":"Zhao","year":"2014","journal-title":"[J] Int J Med Sci"},{"issue":"11","key":"10.1016\/j.cellsig.2021.110038_bb0115","article-title":"Elevated expression of AKR1C3 increases resistance of cancer cells to ionizing radiation via modulation of oxidative stress","volume":"9","author":"Xiong","year":"2014","journal-title":"[J] PLoS One"},{"issue":"4","key":"10.1016\/j.cellsig.2021.110038_bb0120","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1021\/acsmedchemlett.8b00484","article-title":"Bioisosteres of indomethacin as inhibitors of aldo-keto reductase 1C3","volume":"10","author":"Lolli","year":"2019","journal-title":"[J] ACS Med Chem Lett"},{"issue":"12","key":"10.1016\/j.cellsig.2021.110038_bb0125","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1080\/13543776.2017.1379503","article-title":"Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review","volume":"27","author":"Penning","year":"2017","journal-title":"[J] Expert Opin Ther Pat"},{"issue":"7","key":"10.1016\/j.cellsig.2021.110038_bb0130","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/pros.24118","article-title":"Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer","volume":"81","author":"Graham","year":"2021","journal-title":"[J] Prostate"},{"issue":"11","key":"10.1016\/j.cellsig.2021.110038_bb0135","article-title":"Influence of indomethacin on steroid metabolism: endocrine disruption and confounding effects in urinary steroid profiling of anti-doping analyses","volume":"10","author":"Stoll","year":"2020","journal-title":"[J] Metabolites"},{"issue":"6","key":"10.1016\/j.cellsig.2021.110038_bb0140","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1021\/jm3017656","article-title":"Development of potent and selective indomethacin analogues for the inhibition of AKR1C3 (Type 5 17\u03b2-hydroxysteroid dehydrogenase\/prostaglandin F synthase) in castrate-resistant prostate cancer","volume":"56","author":"Liedtke","year":"2013","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.cellsig.2021.110038_bb0145","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.bbrc.2018.10.095","article-title":"Imatinib mesylate elicits extracellular signal-related kinase (ERK) activation and enhances the survival of gamma-irradiated epithelial cells","volume":"506","author":"Lee","year":"2018","journal-title":"[J] Biochem Biophys Res Commun"},{"issue":"1","key":"10.1016\/j.cellsig.2021.110038_bb0150","doi-asserted-by":"crossref","first-page":"9535","DOI":"10.1038\/s41598-017-10373-3","article-title":"Adhesion to stromal cells mediates imatinib resistance in chronic myeloid leukemia through ERK and BMP signaling pathways","volume":"7","author":"Kumar","year":"2017","journal-title":"[J] Sci Rep"},{"issue":"10","key":"10.1016\/j.cellsig.2021.110038_bb0155","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1080\/10428190701644348","article-title":"HMGA2 levels in CML: reflective of miRNA gene regulation in a hematopoietic tumor?","volume":"48","author":"Godley","year":"2007","journal-title":"[J] Leuk Lymphoma"},{"issue":"17","key":"10.1016\/j.cellsig.2021.110038_bb0160","first-page":"3574","article-title":"miRNA-21 sensitizes gastrointestinal stromal tumors (GISTs) cells to Imatinib via targeting B-cell lymphoma 2 (Bcl-2)","volume":"20","author":"Cao","year":"2016","journal-title":"[J] Eur Rev Med Pharmacol Sci"},{"issue":"12","key":"10.1016\/j.cellsig.2021.110038_bb0165","first-page":"6511","article-title":"MiRNA-210: a current overview.[J]","volume":"37","author":"Bavelloni","year":"2017","journal-title":"Anticancer Res."},{"issue":"19","key":"10.1016\/j.cellsig.2021.110038_bb0170","first-page":"8468","article-title":"MiRNA-409-5p dysregulation promotes imatinib resistance and disease progression in children with chronic myeloid leukemia","volume":"23","author":"Liu","year":"2019","journal-title":"[J] Eur Rev Med Pharmacol Sci"},{"issue":"1","key":"10.1016\/j.cellsig.2021.110038_bb0175","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1089\/jir.2012.0062","article-title":"Regulation of human RNase-L by the miR-29 family reveals a novel oncogenic role in chronic myelogenous leukemia.[J]","volume":"33","author":"Lee","year":"2013","journal-title":"J. Interf. Cytokine Res."},{"issue":"3","key":"10.1016\/j.cellsig.2021.110038_bb0180","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.leukres.2012.12.003","article-title":"Decreased microRNA-30a levels are associated with enhanced ABL1 and BCR-ABL1 expression in chronic myeloid leukemia","volume":"37","author":"Liu","year":"2013","journal-title":"[J] Leuk Res"},{"issue":"2","key":"10.1016\/j.cellsig.2021.110038_bb0185","first-page":"61","article-title":"miR-155 down regulation by LNA inhibitor can reduce cell growth and proliferation in PC12 cell line","volume":"3","author":"Kouhkan","year":"2011","journal-title":"[J] Avicenna J Med Biotechnol"},{"issue":"18","key":"10.1016\/j.cellsig.2021.110038_bb0190","first-page":"1450","article-title":"Effects of microRNA-379-5p on proliferation, migration and invasion of hepatocellular carcinoma cell line.[J]","volume":"96","author":"Chen","year":"2016","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"6","key":"10.1016\/j.cellsig.2021.110038_bb0195","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.3892\/or.2017.5607","article-title":"MicroRNA-379-5p plays a tumor-suppressive role in human bladder cancer growth and metastasis by directly targeting MDM2.[J]","volume":"37","author":"Wu","year":"2017","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.cellsig.2021.110038_bb0200","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.2147\/CMAR.S253504","article-title":"MicroRNA-379-5p\/YBX1 axis regulates cellular EMT to suppress migration and invasion of nasopharyngeal carcinoma cells","volume":"12","author":"Zhang","year":"2020","journal-title":"[J] Cancer Manag. Res"},{"issue":"7","key":"10.1016\/j.cellsig.2021.110038_bb0205","article-title":"miR-379 regulates cyclin B1 expression and is decreased in breast cancer","volume":"8","author":"Khan","year":"2013","journal-title":"[J] PLoS One"},{"issue":"3","key":"10.1016\/j.cellsig.2021.110038_bb0210","doi-asserted-by":"crossref","first-page":"867","DOI":"10.3892\/ijo.2017.4072","article-title":"MicroRNA-379 inhibits metastasis and epithelial-mesenchymal transition via targeting FAK\/AKT signaling in gastric cancer.[J]","volume":"51","author":"Xu","year":"2017","journal-title":"Int. J. Oncol."}],"container-title":["Cellular Signalling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0898656821001273?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0898656821001273?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T02:09:44Z","timestamp":1718762984000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0898656821001273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":42,"alternative-id":["S0898656821001273"],"URL":"https:\/\/doi.org\/10.1016\/j.cellsig.2021.110038","relation":{},"ISSN":["0898-6568"],"issn-type":[{"value":"0898-6568","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AKR1C3 decreased CML sensitivity to Imatinib in bone marrow microenvironment via dysregulation of miR-379-5p","name":"articletitle","label":"Article Title"},{"value":"Cellular Signalling","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellsig.2021.110038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110038"}}